Novel Copper Chelators Enhance Spatial Memory and Biochemical Outcomes in Alzheimer's Disease Model

Area of Science:

• Neuroscience
• Medicinal Chemistry
• Pharmacology

Background:

• Alzheimer's disease pathology involves copper dysregulation and beta-amyloid aggregation.
• Copper chelation is a potential therapeutic strategy to mitigate neurodegeneration.
• Novel molecular compounds are being investigated for their neuroprotective properties.

Purpose of the Study:

• To synthesize and evaluate novel imine and quinoline-based compounds as copper chelators for Alzheimer's disease.
• To assess the in vitro, in silico, and in vivo efficacy of these compounds in reversing neurodegeneration.
• To identify lead candidates for further drug development.

Main Methods:

• Synthesis and characterization of eight imines and one quinoline derivative.
• In vitro assessment of copper extraction from Cu-β-amyloid complexes using electron paramagnetic resonance (EPR) spectroscopy.
• In silico prediction of absorption, distribution, metabolism, and excretion (ADME) properties.
• Cellular studies evaluating cytotoxicity, lipid peroxidation, and DNA damage.
• In vivo studies using a streptozotocin (STZ)-induced Alzheimer's rat model to assess neuroinflammation, oxidative stress, copper homeostasis, and spatial memory.

Main Results:

• Compounds L09, L10, and L11 demonstrated significant in vitro copper extraction from Cu-β-amyloid complexes.
• In silico analysis predicted favorable ADME properties for L09, L10, and L11, indicating potential for oral administration and blood-brain barrier penetration.
• Compounds L09 and L10 showed low cytotoxicity in cellular studies and reduced beta-amyloid-induced damage.
• In vivo studies demonstrated that compound L10 significantly reduced neuroinflammation, oxidative stress, and restored copper homeostasis in the hippocampus, improving spatial memory.

Conclusions:

• Novel copper chelators, particularly compound L10, show significant therapeutic potential for Alzheimer's disease.
• Compound L10 warrants further investigation as a promising candidate for Alzheimer's treatment due to its neuroprotective and memory-enhancing effects.
• Targeted copper chelation represents a viable therapeutic strategy for Alzheimer's disease, supported by comprehensive in silico, in vitro, and in vivo data.